Kornimate/medical-research-clean huggingface dataset:
paullinia cupana for anorexia in oncologic patients

Conditions: Cancer-related Problem/Condition; Anorexia; Loss of Weight

Summary: denutrition, lost of weight and anorexia are present in many oncologic patients at any time of the disease. anorexia is the spontaneous loss of appetite and many changes in the metabolism are made in this case, leading to this syndrome called anorexia-cachexia, that includes changes in the tumoral response and inflammatory pathways. the guaraná (paullinia cupana) is originally from brazil and venezuela and has been used culturally for headaches, muscle pains, depression and others. as it has shown a good response and tolerability for fatigue, the investigators decide to try guaraná for anorexia. patients will receive guaraná as capsules of 50 mg twice daily, for 4 weeks, and will be weighted and respond questionaries about quality of life.

patients 18 years and older, diagnosed with any cancer, that is losing weight and have anorexia will be selected. they must have normal levels of creatinine, thyroid evaluation and hepatic function. if they are taking corticosteroid, they must keep losing weight and refer anorexia, as well as if they are on treatment with chemotherapy. patients will receive 50mg of the guaraná twice daily for 4 weeks. every week will be an evaluation of the weight, level of appetite and answer 2 questionaries of quality of life and level of symptoms (fact-g and mdasi). this is a fase ii study, open-label, no randomized, with two steps following ¨two stages of simon¨ model. first step 18 patients will be included and if there are 3 good responses second step will follow, including 17 more patients. response will be considered if there is at least 5% of gain in the weight.

Eligibility criteria:
inclusion criteria: * adults (18 years old and older) * palliative care or oncologic treatment * loss of weight * anorexia exclusion criteria: * gastrointestinal obstruction * blood pressure not controlled * diabetes not treated

Keywords: anorexia paullinia cupana loss of weight
middle meningeal artery (mma) embolization compared to traditional surgical strategies to treat chronic subdural hematomas (csdh)

Conditions: Chronic Subdural Hematoma

Summary: chronic subdural hematoma (csdh) is a common hematologic problem particularly in older patients. the purpose of this study is to evaluate the safety and efficacy of middle meningeal artery (mma) embolization compared to traditional surgical strategies for patients presenting with chronic subdural hematoma (csdh). although mma embolization is minimally-invasive procedure that is routinely used for the treatment of tumors or vascular formations (1), this study investigates the use of an established procedure for a new disease state.

the purpose of the research study is to evaluate the safety and efficacy of a new, less-invasive procedure to treat chronic subdural hematoma (csdh). a subdural hematoma occurs when blood collects on the brain's surface beneath the skull. subdural hematomas can be life-threatening. they usually result from a head injury. this study will compare the new procedure to conventional surgical treatment of chronic subdural hematoma (csdh). the new procedure is called middle meningeal artery embolization (mma). current or conventional treatment of chronic subdural hematoma (csdh) involves surgery (burr hole drainage and craniotomy) to access and remove the cause of the bleeding that is causing the subdural hematoma. the new procedure, mma embolization, involves guiding a catheter that is inserted into a blood vessel to the area of the brain that is supplying blood to the subdural hematoma. particles or a special type of glue will be released to stop the bleeding that is causing the subdural hematoma. this technique has been used to treat other brain conditions, for example, (to treat tumors or malformation of blood vessels).

Eligibility criteria:
inclusion criteria: * age 18 or older * participant or surrogate must be english speaking * subjects must have a diagnosis of chronic or acute-on subdural hematoma based on brain imaging, as documented by an * one or more symptoms attributable to chronic sdh including headache cognitive impairment, gait instability, seizure, or mild focal neurologic deficit. * in opinion of investigator or the subject's referring physician, the subject has failed conservative management. exclusion criteria: * the subdural hematoma is causing mass effect significant enough to cause marked or progressive neurologic impairment * any requirement for urgent surgical evacuation is necessary * life expectancy is less than 6 months in the opinion of the subject's primary physician * markedly tortuous vasculature precluding safe endovascular access, as assessed on angiogram * acute subdural hematomas * health insurance doesn't cover mma embolization or performing surgeon and follow up visits are considered out of network. * pregnancy
assessment of efficacy and safety of hcq and antibiotics administrated to patients covid19(+)

Conditions: Patients With COVID19

Summary: the study will assess the number of patients who become asymptomatic from clinical signs of covid19 and will assess the efficacy of hydroxychloroquine (hcq) and azithromycine effects on paucisymptomatic patients with ou without co-morbidities


Eligibility criteria:
inclusion criteria: * confirmed covid19 (+) * qt\<500ms * no severity criteria * pauci-symptomatique patients * signed consent form exclusion criteria: * no confirmed patient covid19 * severity criteria * known allegies to macrolides and hcq * treated with hcq within 1 month prior to inclusion * hepatitis insufficiency * renal insufficiency * treatment no indicated with azithro and hcq * hypovolemia * complete brach block * retinopathia * psoriasis * pregnancy or breastfeeding
testing the effectiveness of voices as implemented by std & hiv prevention agencies in the us and pr

Conditions: Sexually Transmitted Diseases

Summary: the purpose of the project is to determine whether the voices/voces intervention, that was shown to be effective in a research study, is still effective when delivered by std/hiv prevention agencies. voices/voces is a brief, single-session intervention for african-american and latino adult men and women at high risk for std/hiv. it encourages condom use and improves condom negotiation skills. a health educator delivers the intervention to groups of 4 to 8 clinic patients in a private room. groups are made up of people of the same sex and same race or ethnicity. information on std/hiv risk behaviors and condom use is delivered by culturally-specific videos, group discussion, and a poster presenting features of various condom brands. participants role-play condom negotiation modeled in the videos. at the end of the session they are given sample condoms of their choice. in this project, health educators from the health departments of new york city and san juan, puerto rico conducted the voices/voces intervention with a sample of patients from one std clinic in each of their cities. researchers helped the health departments test whether the intervention is effective when local health educators deliver it.

this project was an rct with 1699 patients assigned to receive the voices/voces intervention and 1707 to receive standard of care at each of the two std clinics (total n=3406). participant outcomes and their measures are: 1. change in knowledge and attitudes about condoms as determined by participant profile and survey data 2. condom acquisition as determined by project coupon redemption data 3. std incidence as determined by medical chart review and/or surveillance data in addition, cost accounting data on the amounts and types of resources required to implement the intervention were used to evaluate the intervention's cost-effectiveness. process evaluation data allow identification of factors that influenced intervention implementation and the effectiveness of the intervention.

Eligibility criteria:
inclusion criteria: * std infection at time of recruitment * accept treatment for std infection at time of recruitment exclusion criteria: * age under 18 years

Keywords: controlled clinical trial behavioral intervention prevention intervention
a study of tarceva (erlotinib) in combination with platinum based chemotherapy in patients with non-small cell lung cancer.

Conditions: Non-Small Cell Lung Cancer

Summary: this study will evaluate the efficacy and safety of sequential administration of tarceva and gemcitabine/platinum chemotherapy in patients with stage iiib/iv non-small cell lung cancer. patients will be randomized to receive tarceva (150 mg po) or placebo on days 15-28 of a 4 week cycle of intravenous platinum-based chemotherapy, for a total of 6 cycles. the anticipated time on study treatment is until disease progression or unacceptable toxicity.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * histologically documented advanced or recurrent stage iiib or iv non-small cell lung cancer; * measurable disease; * no previous chemotherapy for non-small cell lung cancer. exclusion criteria: * unstable systemic disease; * any other malignancies in the last 5 years.
study of prevalence of eating disorder in liver transplant patients

Conditions: Eating Disorders; Eating Disorder Binge; Liver Transplant; Complications; Alcohol Use Disorder; Cirrhosis Alcoholic

Summary: the main goal of this observational study is to measure the prevalence of binge eating disorder in liver transplant patients by evaluating the responses to the bulimia test. secondary objectives of the study are to: * determine the prevalence of binge eating disorders in liver transplant patients following alcoholic cirrhosis, evaluated by the bulimia test; * study the association between the presence of eating disorder behaviours and liver damage : hepatic steatosis and fibrosis determined by fibroscan (transient elastography and controlled attenuation parameter) * study the association between presence of eating disorder behaviours and alcohol use disorder, measured by alcohol use disorders identification test-consumption


Eligibility criteria:
inclusion criteria: * over 18 years old * had a liver transplant and followed at university hospital of poitiers * responded to the bulimia test-revised and to the alcohol use disorders identification test-consumption * had a fibroscan within the year exclusion criteria: * patient without fibroscan and not responded to both scale : bulimia test-revised and alcohol use disorders identification test-consumption
reduction in the occurrence of center-involved diabetic macular edema

Conditions: Diabetic Retinopathy

Summary: the purpose of this study is to determine if ruboxistaurin can help slow the worsening of an eye disease called macular edema in patients with diabetes.


Eligibility criteria:
inclusion criteria: * type 1 or type 2 diabetes * 18 years or older * non-clinically significant diabetic macular edema * mild to moderate diabetic retinopathy in the study eye, vitreous hemorrhage in the study eye * relatively good vision (20/30 or better) exclusion criteria: * surgery or laser treatment in the study eye * glaucoma in the study eye * glycosylated hemoglobin (hba1c) greater than 11%, or systolic blood pressure greater than 170 millimeters of mercury (mmhg) * liver disease, dialysis or renal transplant
pharmacokinetic interaction study in indonesian tuberculosis patients indonesia

Conditions: Tuberculosis

Summary: pharmacokinetic study in tb patients to determine the effect of rifampicin on the pharmacokinetic profile of moxifloxacin.

tuberculosis is an infectious disease that still causes many victims in the developing world, especially in indonesia. rifampicin, isoniazid and ethambutol are the cornerstone of the current treatment. the disadvantage of the current treatment is the long, six-months, duration of the treatment. this long duration contributes to suboptimal adherence to the tb drugs.thus, there is a very urgent need to evaluate drugs that may help shortening tb treatment. the fluoroquinolone moxifloxacin has shown early bactericidal activity (eba) in patients with pulmonary tb, and has shown rapid and reliable sterilization. rifampicin is a strong inducer of the cyp enzymes, but it also induces phase ii metabolism. as moxifloxacin is metabolized by phase ii metabolism, rifampicin could cause a decrease in the plasma concentrations of moxifloxacin. therefore, a pharmacokinetic interaction study is warranted.

Eligibility criteria:
inclusion criteria: * indonesian afb negative tuberculosis patients who are in the last two months of the continuation phase of their six-month-antituberculosis treatment. * subject is 18-55 years of age at the day of the first dosing of study medication. * subject has a normal ecg * subjects bodyweight is \>35kg * use of rifampicin and isoniazid exclusion criteria: * pregnant or lactating * history or condition that might interfere with drug absorption, distribution, metabolism or excretion, including ileus, gastric paresis, liver and renal dysfunction, diabetes mellitus. * presence of contraindications for moxifloxacin or use of drugs that are known to interact with moxifloxacin. * subject is not able and/or not willing to sign the informed consent form.

Keywords: tuberculosis
gastrointestinal cancer in children and adolescents

Conditions: Gastrointestinal Cancer; Colorectal Cancer; Gastric Cancer; Hepatoblastoma; Hepatocellular Carcinoma; Burkitt Lymphoma; Neuroendocrine Tumors

Summary: the goal of this observational population-based cohort study is to investigate the clinical characteristics and outcomes of children and adolescents with primary gastrointestinal malignancies registered in the publicly available surveillance, epidemiology, and end results (seer) 17 database during 2000-2019.

the investigators aim to describe the patient and tumor characteristics, treatments, and outcomes of children and adolescents diagnosed with primary gastrointestinal malignancies, and to analyze these data for trends over time. in addition, the investigators want to explore independent prognostic factors for overall survival. finally, the investigators want to describe subsequent primary malignancies diagnosed among patients from the study cohort, as well as to calculate their risk of developing a second primary cancer relative to the general population. data on children (aged 0-17 years at diagnosis) and young people aged 18-24 years at diagnosis are analyzed separately. special focus is laid on patients with primary carcinomas of the gastrointestinal tract; particularly colorectal carcinoma.

Eligibility criteria:
inclusion criteria: * age at primary gastrointestinal cancer diagnosis \<25 years * diagnosis of a primary gastrointestinal malignancy as an individual's first primary malignancy exclusion criteria: * none

Keywords: seer gastrointestinal cancer malignant child pediatric adolescent
ongoing warfarin and coronary stenting

Conditions: Acute Coronary Syndrome; Atrial Fibrillation

Summary: patients on warfarin treatment pose particular problems when undergoing percutaneous coronary intervention with stent implantation (pci-s), because of the poor definition of the optimal antithrombotic strategies to be adopted both peri-procedurally and during the 4 (or more) weeks after pci-s, when dual antiplatelet therapy with aspirin and clopidogrel is recommended. in the absence of solid evidence-based data, no definite recommendations for the management of this patient subset are currently given in the guidelines on percutaneous coronary intervention issued by the most prominent cardiology associations. indeed, a high variability has been reported in the current antithrombotic strategies, which may consist in either the temporary substitution of warfarin by dual antiplatelet treatment or the combination of warfarin and aspirin or clopidogrel or both. peri-procedural bridging therapy with either intravenous unfractionated or subcutaneous low-molecular-weight heparin is also variably carried out. purpose of this registry is to determine in patients on warfarin treatment undergoing pci-s: 1) the contemporary peri-procedural and medium-term antithrombotic management; and 2) the relative safety and efficacy of the various antithrombotic regimens.

patients on oral anticoagulation with vitamin-k antagonists who undergo pci-s will be prospectively included in the registry and follow up for 12 months

Eligibility criteria:
inclusion criteria: * patients with ongoing warfarin treatment. exclusion criteria: * none

Keywords: oral anticoagulation warfarin percutaneous coronary intervention stent antiplatelet agents
an open-label study of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: this is a multicenter, open-label, fixed dose, 26 week study of patients with mdd. eligible patients from the lead-in studies will enter the open-label safety study at the screening/baseline visit (visit 1/day 1), at which point patient eligibility will be assessed and informed consent obtained.

at the screening/baseline visit (visit 1/day 1), which is the same visit as visit 8/day 43 of the lead-in study, eligible patients will receive open-label lumateperone 42 mg once daily for approximately 26 weeks. patients will continue their background adt from the lead-in study. patients will be seen for weekly visits through visit 5/week 4. thereafter, visits will occur every two weeks. a safety follow-up visit will occur on visit 17/day 197, approximately 2 weeks after the last dose of open-label lumateperone 42 mg.

Eligibility criteria:
inclusion criteria: 1. in the opinion of the investigator, patients must have safely completed the lead-in study. 2. patient is taking their adt as prescribed from the lead-in study. exclusion criteria: 1. in the opinion of the investigator, the patient is unable to comply with study procedures or judged to be inappropriate for the study. 2. in the opinion of the investigator, the patient has a significant risk for suicidal behavior during the course of her/his participation in the study or is considered to be an imminent danger to her/himself or others, and/or: 1. at the screening/baseline visit, the patient scores "yes" on suicidal ideation items 4 or 5 of the c ssrs "since last visit" version; 2. at the screening/baseline visit, the patient scores ≥ 5 on the madrs item 10 (suicidal thoughts). 3. based on the investigator's clinical judgement, any abnormal clinical laboratory test or ecg results obtained throughout the lead-in study that are considered clinically significant and preclude safe participation in the study.

Keywords: adjunctive mdd therapy
the effect of patient position on postdural puncture headache

Conditions: Pregnancy; Headache

Summary: we aimed to investigate the association between the position in which spinal anesthesia was performed and postdural puncture headache occurrence.

records of patients who underwent caesarean section between january, 2013 and november, 2013 with spinal anesthesia will be retrospectively examined. demographic data of patients, comorbid diseases, position of patient while performing spinal anesthesia, the number of spinal puncture attempts will be recorded.

Eligibility criteria:
inclusion criteria: * patients older than 18 years were included exclusion criteria: * conversion to general anesthesia was the exclusion criteria.
tumour registry colorectal cancer

Conditions: Colorectal Cancer

Summary: to describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in germany.

the tkk is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of colorectal cancer in germany. the registry will follow patients for up to five years. it will identify common therapeutic sequences and changes in the treatment of the disease. at inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. during the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. the impact of nutrition (conut) and physical activity (conut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (cotox) and the final phase of the palliative process (colife). based on the available data a prognostic score will be developed.

Eligibility criteria:
inclusion criteria: * colorectal cancer * 18 years and older * antineoplastic treatment exclusion criteria: * no colorectal cancer * below 18 years * no antineoplastic treatment

Keywords: colorectal cancer advanced colorectal cancer epidemiology health services research germany registry palliative care palliative treatment adjuvant drug therapy nutrition assessment physical activity
mobicox: study of meloxicam to reduce prostate swelling in permanent seed prostate brachytherapy

Conditions: Prostatic Neoplasms

Summary: swelling of the prostate can occur during and after a brachytherapy. this swelling can cause urinary problems ranging from difficulty voiding to urinary retention. the purpose of this study is to investigate whether mobicox started one week before brachytherapy and then continued afterwards is more effective in reducing the risk of needing a catheter than mobicox given only afterwards.


Eligibility criteria:
inclusion criteria: * eligible to receive prostate brachytherapy as per the ontario provincial guidelines will be eligible for this study (i.e. prostate specific antigen \[psa\] \< 10, gleason score \<7, stage \<= t2a) exclusion criteria: * patients already taking anti-inflammatory drugs * patients with allergic-type reactions, including asthma and urticaria, to aspirin or nonsteroidal anti-inflammatory agents (see product information)